Carnitine in metabolic disease: Potential for pharmacological intervention

被引：70

作者：

Arduini, Arduino ^{[1
]}

Bonomini, Mario ^{[2
]}

Savica, Vincenzo ^{[3
]}

Amato, Antonino ^{[4
]}

Zammit, Victor

机构：

[1] Iperboreal Pharma Srl, R&D Dept, Chieti, Italy

[2] Univ Hosp Chieti, Dept Nephrol & Dialysis, Chieti, Italy

[3] Univ Messina, Nephrol & Dialysis Unit, Messina, Italy

[4] Sigma Tau Pharmaceut Spa, Clin Res Unit, Pomezia, Italy

来源：

PHARMACOLOGY & THERAPEUTICS | 2008年 / 120卷 / 02期

关键词：

L-carnitine; Hemodialysis; Uremia; Peritoneal dialysis; Insulin resistance; Diabetes; Metabolism; Dyslipidemia;

D O I：

10.1016/j.pharmthera.2008.08.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

L-carnitine (LC) deficiency is commonly observed in chronic hemodialysis (HD) patients. As a result of this and other causes of secondary LC deficiencies, LC has been described as a "conditionally essential nutrient" or "conditional vitamin". Although a large number of clinical trials regarding the beneficial effects of LC administration in HD patients have been published, some controversy about its use in this indication persists. In this article, we will review the use of LC in dialysis patients, by focussing mainly on those experimental and clinical data supporting the notion that supra-physiological concentrations of LC in plasma and target organs may exert beneficial effects on several metabolic parameters that have derangements of a common origin (e.g. insulin resistance, type 2 diabetes, dyslipidemia) and which are frequently present in end-stage renal disease (ESRD) patients undergoing dialysis. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：149 / 156

页数：8

共 82 条

[61] Common misconceptions about levocarnitine and dialysis [J].